1	Therapeutic	Therapeutic	B-NP	JJ	O	2	NMOD	0
2	angiogenesis	angiogenesis	I-NP	NN	O	6	NMOD	3	angiogenesis
3	:	:	O	:	O	2	P	0
4	a	a	B-NP	DT	O	6	NMOD	0
5	complex	complex	I-NP	JJ	O	6	NMOD	0
6	problem	problem	I-NP	NN	O	0	ROOT	0
7	requiring	require	B-VP	VBG	O	6	NMOD	0
8	a	a	B-NP	DT	O	10	NMOD	0
9	sophisticated	sophisticated	I-NP	JJ	O	10	NMOD	0
10	approach	approach	I-NP	NN	O	7	OBJ	0
11	.	.	O	.	O	6	P	0

1	Blood	Blood	B-NP	NN	O	4	NMOD	0
2	and	and	O	CC	O	4	NMOD	0
3	vascular	vascular	B-NP	JJ	O	4	NMOD	0
4	disorders	disorder	I-NP	NNS	O	5	SUB	0
5	underlie	underlie	B-VP	VBP	O	0	ROOT	0
6	a	a	B-NP	DT	O	7	NMOD	0
7	plethora	plethora	I-NP	NN	O	5	OBJ	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	pathologic	pathologic	B-NP	JJ	O	10	NMOD	0
10	conditions	condition	I-NP	NNS	O	8	PMOD	0
11	and	and	O	CC	O	5	VMOD	0
12	are	be	B-VP	VBP	O	5	VMOD	0
13	the	the	B-NP	DT	O	17	NMOD	0
14	single	single	I-NP	JJ	O	16	AMOD	0
15	most	most	I-NP	RBS	O	16	AMOD	0
16	frequent	frequent	I-NP	JJ	O	17	NMOD	0
17	cause	cause	I-NP	NN	O	12	PRD	0
18	of	of	B-PP	IN	O	17	NMOD	0
19	human	human	B-NP	JJ	O	20	NMOD	0
20	disease	disease	I-NP	NN	O	18	PMOD	0
21	.	.	O	.	O	5	P	0

1	Ischemia	Ischemia	B-NP	NNP	O	9	SUB	0
2	,	,	O	,	O	1	P	0
3	involving	involve	B-VP	VBG	O	1	NMOD	0
4	restricted	restricted	B-NP	JJ	O	6	NMOD	0
5	blood	blood	I-NP	NN	O	6	NMOD	0
6	flow	flow	I-NP	NN	O	3	OBJ	0
7	to	to	B-PP	TO	O	6	NMOD	0
8	tissues	tissue	B-NP	NNS	O	7	PMOD	0
9	is	be	B-VP	VBZ	O	0	ROOT	0
10	the	the	B-NP	DT	O	13	NMOD	0
11	most	most	I-NP	RBS	O	12	AMOD	0
12	common	common	I-NP	JJ	O	13	NMOD	0
13	consequence	consequence	I-NP	NN	O	9	PRD	0
14	of	of	B-PP	IN	O	13	NMOD	0
15	vessel	vessel	B-NP	NN	O	16	NMOD	0
16	dysfunction	dysfunction	I-NP	NN	O	14	PMOD	6	dysfunction
17	resulting	result	B-VP	VBG	O	16	NMOD	0
18	in	in	B-PP	IN	O	17	VMOD	0
19	the	the	B-NP	DT	O	20	NMOD	0
20	disruption	disruption	I-NP	NN	O	28	NMOD	11	disruption
21	of	of	B-PP	IN	O	20	NMOD	0
22	oxygen	oxygen	B-NP	NN	O	25	NMOD	0
23	and	and	I-NP	CC	O	25	NMOD	0
24	nutrient	nutrient	I-NP	NN	O	25	NMOD	0
25	delivery	delivery	I-NP	NN	O	21	PMOD	0
26	and	and	O	CC	O	28	NMOD	0
27	the	the	B-NP	DT	O	28	NMOD	0
28	accumulation	accumulation	I-NP	NN	O	18	PMOD	0
29	of	of	B-PP	IN	O	28	NMOD	0
30	waste	waste	B-NP	NN	O	31	NMOD	0
31	metabolites	metabolite	I-NP	NNS	O	29	PMOD	0
32	.	.	O	.	O	9	P	0

1	Cells	Cell	B-NP	NNS	O	2	SUB	0
2	can	can	B-VP	MD	O	0	ROOT	0
3	not	not	I-VP	RB	O	2	VMOD	0
4	survive	survive	I-VP	VB	O	2	VC	5	survive
5	extended	extend	I-VP	VBN	O	7	NMOD	0
6	severe	severe	B-NP	JJ	O	7	NMOD	0
7	ischemia	ischemia	I-NP	NN	O	4	OBJ	0
8	but	but	O	CC	O	2	VMOD	0
9	may	may	B-VP	MD	O	2	VMOD	0
10	be	be	I-VP	VB	O	9	VC	0
11	able	able	B-ADJP	JJ	O	10	PRD	0
12	to	to	B-VP	TO	O	13	VMOD	0
13	adapt	adapt	I-VP	VB	O	11	AMOD	0
14	to	to	B-PP	TO	O	13	VMOD	0
15	a	a	B-NP	DT	O	17	NMOD	0
16	moderate	moderate	I-NP	JJ	O	17	NMOD	0
17	condition	condition	I-NP	NN	O	14	PMOD	0
18	where	where	B-ADVP	WRB	O	17	NMOD	0
19	diffusion	diffusion	B-NP	NN	O	26	SUB	0
20	to	to	B-PP	TO	O	19	NMOD	0
21	and	and	I-PP	CC	O	20	PMOD	0
22	from	from	I-PP	IN	O	20	PMOD	0
23	bordering	border	B-VP	VBG	O	19	NMOD	0
24	nonischemic	nonischemic	B-NP	JJ	B-protein	25	NMOD	0
25	regions	region	I-NP	NNS	I-protein	23	OBJ	0
26	sustains	sustain	B-VP	VBZ	O	18	SBAR	0
27	vital	vital	B-NP	JJ	O	28	NMOD	0
28	functions	function	I-NP	NNS	O	26	OBJ	0
29	.	.	O	.	O	2	P	0

1	Under	Under	B-PP	IN	O	11	VMOD	0
2	this	this	B-NP	DT	O	3	NMOD	0
3	condition	condition	I-NP	NN	O	1	PMOD	0
4	,	,	O	,	O	11	P	0
5	the	the	B-NP	DT	O	7	NMOD	0
6	secondary	secondary	I-NP	JJ	O	7	NMOD	0
7	functions	function	I-NP	NNS	O	11	SUB	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	effected	effect	B-NP	VBN	B-cell_type	10	NMOD	16	effected
10	cells	cell	I-NP	NNS	I-cell_type	8	PMOD	0
11	are	be	B-VP	VBP	O	22	VMOD	0
12	likely	likely	B-ADJP	JJ	O	11	PRD	0
13	to	to	B-VP	TO	O	14	VMOD	0
14	be	be	I-VP	VB	O	12	AMOD	0
15	impaired	impair	I-VP	VBN	O	14	VC	0
16	,	,	O	,	O	22	P	0
17	and	and	O	CC	O	22	VMOD	0
18	a	a	B-NP	DT	O	21	NMOD	0
19	new	new	I-NP	JJ	O	21	NMOD	0
20	metabolic	metabolic	I-NP	JJ	O	21	NMOD	0
21	equilibrium	equilibrium	I-NP	NN	O	22	SUB	0
22	is	be	B-VP	VBZ	O	0	ROOT	0
23	established	establish	I-VP	VBN	O	22	VC	0
24	,	,	O	,	O	23	P	0
25	determined	determine	B-VP	VBN	O	23	VMOD	0
26	by	by	B-PP	IN	O	25	VMOD	0
27	the	the	B-NP	DT	O	28	NMOD	0
28	level	level	I-NP	NN	O	32	NMOD	0
29	of	of	B-PP	IN	O	28	NMOD	0
30	cross-diffusion	cross-diffusion	B-NP	NN	O	29	PMOD	0
31	and	and	I-NP	CC	O	32	NMOD	0
32	degree	degree	I-NP	NN	O	26	PMOD	0
33	of	of	B-PP	IN	O	32	NMOD	0
34	hypoxia	hypoxia	B-NP	NN	O	33	PMOD	0
35	.	.	O	.	O	22	P	0

1	In	In	B-PP	IN	O	19	VMOD	0
2	tissues	tissue	B-NP	NNS	O	1	PMOD	0
3	with	with	B-PP	IN	O	2	NMOD	0
4	a	a	B-NP	DT	O	8	NMOD	0
5	normally	normally	I-NP	RB	O	6	AMOD	0
6	high	high	I-NP	JJ	O	8	NMOD	0
7	metabolic	metabolic	I-NP	JJ	O	8	NMOD	0
8	turnover	turnover	I-NP	NN	O	3	PMOD	0
9	such	such	B-PP	JJ	O	10	PMOD	0
10	as	as	I-PP	IN	O	8	NMOD	0
11	skeletal	skeletal	B-NP	JJ	O	14	NMOD	0
12	and	and	I-NP	CC	O	14	NMOD	0
13	cardiac	cardiac	I-NP	JJ	O	14	NMOD	0
14	muscle	muscle	I-NP	NN	O	10	PMOD	0
15	,	,	O	,	O	19	P	0
16	even	even	B-NP	RB	O	18	NMOD	0
17	mild	mild	I-NP	JJ	O	18	NMOD	0
18	ischemia	ischemia	I-NP	NN	O	19	SUB	0
19	causes	cause	B-VP	VBZ	O	0	ROOT	0
20	hypoxia	hypoxia	B-NP	NN	O	26	NMOD	0
21	,	,	O	,	O	26	P	0
22	acidosis	acidosis	B-NP	NN	O	26	NMOD	0
23	,	,	O	,	O	26	P	0
24	and	and	O	CC	O	26	NMOD	0
25	depressed	depress	B-VP	VBN	O	26	NMOD	0
26	function	function	B-NP	NN	O	19	OBJ	0
27	(	(	O	(	O	29	DEP	0
28	contractility	contractility	B-NP	NN	O	29	DEP	0
29	)	)	O	)	O	26	NMOD	0
30	and	and	O	CC	O	19	VMOD	0
31	eventually	eventually	B-VP	RB	O	32	VMOD	0
32	threatens	threaten	I-VP	VBZ	O	19	VMOD	0
33	myocyte	myocyte	B-NP	NN	O	34	NMOD	0
34	viability	viability	I-NP	NN	O	37	NMOD	0
35	and	and	O	CC	O	37	NMOD	0
36	organ	organ	B-NP	NN	O	37	NMOD	0
37	function	function	I-NP	NN	O	32	OBJ	0
38	.	.	O	.	O	19	P	0

1	Ischemic	Ischemic	B-NP	JJ	O	3	NMOD	0
2	cardiac	cardiac	I-NP	JJ	O	3	NMOD	0
3	muscle	muscle	I-NP	NN	O	4	SUB	0
4	is	be	B-VP	VBZ	O	0	ROOT	0
5	additionally	additionally	B-ADJP	RB	O	6	AMOD	0
6	vulnerable	vulnerable	I-ADJP	JJ	O	4	PRD	0
7	because	because	B-SBAR	IN	O	4	VMOD	0
8	reperfusion	reperfusion	B-NP	NN	O	9	SUB	0
9	is	be	B-VP	VBZ	O	7	SBAR	0
10	essential	essential	B-ADJP	JJ	O	9	PRD	0
11	for	for	B-PP	IN	O	10	AMOD	0
12	survival	survival	B-NP	NN	O	15	NMOD	0
13	but	but	O	CC	O	15	NMOD	0
14	reperfusion	reperfusion	B-NP	NN	O	15	NMOD	0
15	itself	itself	B-NP	PRP	O	11	PMOD	0
16	poses	pose	B-VP	VBZ	O	4	VMOD	0
17	additional	additional	B-NP	JJ	O	18	NMOD	0
18	stress	stress	I-NP	NN	O	16	OBJ	0
19	principally	principally	B-ADVP	RB	O	20	PMOD	0
20	from	from	B-PP	IN	O	16	VMOD	0
21	increased	increase	B-NP	VBN	O	22	NMOD	0
22	production	production	I-NP	NN	O	20	PMOD	0
23	of	of	B-PP	IN	O	22	NMOD	0
24	free	free	B-NP	JJ	O	25	NMOD	0
25	radicals	radical	I-NP	NNS	O	23	PMOD	0
26	during	during	B-PP	IN	O	22	NMOD	0
27	reoxygenation	reoxygenation	B-NP	NN	O	26	PMOD	0
28	.	.	O	.	O	4	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	latter	latter	I-NP	JJ	O	3	NMOD	0
3	effect	effect	I-NP	NN	O	4	SUB	0
4	is	be	B-VP	VBZ	O	0	ROOT	0
5	called	call	I-VP	VBN	O	4	VC	0
6	reperfusion	reperfusion	B-NP	NN	O	7	NMOD	0
7	injury	injury	I-NP	NN	O	5	VMOD	0
8	and	and	O	CC	O	4	VMOD	0
9	can	can	B-VP	MD	O	4	VMOD	0
10	cause	cause	I-VP	VB	O	9	VC	0
11	as	as	B-NP	IN	O	13	NMOD	0
12	much	much	I-NP	JJ	O	13	NMOD	0
13	damage	damage	I-NP	NN	O	10	OBJ	0
14	as	as	B-PP	IN	O	10	VMOD	0
15	the	the	B-NP	DT	O	16	NMOD	0
16	ischemia	ischemia	I-NP	NN	O	14	PMOD	0
17	.	.	O	.	O	4	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	treatment	treatment	I-NP	NN	O	3	NMOD	0
3	possibilities	possibility	I-NP	NNS	O	8	SUB	0
4	for	for	B-PP	IN	O	3	NMOD	0
5	ischemia-related	ischemia-related	B-NP	JJ	O	7	NMOD	0
6	vascular	vascular	I-NP	JJ	O	7	NMOD	0
7	disease	disease	I-NP	NN	O	4	PMOD	0
8	are	be	B-VP	VBP	O	0	ROOT	0
9	limited	limit	B-ADJP	VBN	O	8	VC	0
10	.	.	O	.	O	8	P	0

1	Lipid/cholesterol-lowering	Lipid/cholesterol-lowering	B-NP	JJ	O	2	NMOD	0
2	agents	agent	I-NP	NNS	O	7	NMOD	0
3	,	,	O	,	O	7	P	0
4	diet	diet	B-NP	NN	O	7	NMOD	0
5	and	and	O	CC	O	7	NMOD	0
6	antiplatelet	antiplatelet	B-NP	JJ	O	7	NMOD	0
7	adherence	adherence	I-NP	NN	O	11	NMOD	0
8	(	(	O	(	O	10	DEP	0
9	aspirin	aspirin	B-NP	NN	O	10	DEP	0
10	)	)	O	)	O	7	NMOD	0
11	therapy	therapy	B-NP	NN	O	12	SUB	19	therapy
12	may	may	B-VP	MD	O	27	VMOD	0
13	help	help	I-VP	VB	O	12	VC	0
14	slow	slow	I-VP	VB	O	13	VMOD	0
15	the	the	B-NP	DT	O	16	NMOD	0
16	progression	progression	I-NP	NN	O	14	OBJ	0
17	of	of	B-PP	IN	O	16	NMOD	0
18	vessel	vessel	B-NP	NN	O	19	NMOD	0
19	disease	disease	I-NP	NN	O	17	PMOD	0
20	in	in	B-PP	IN	O	16	NMOD	0
21	some	some	B-NP	DT	O	22	NMOD	0
22	instances	instance	I-NP	NNS	O	20	PMOD	0
23	;	;	O	:	O	27	P	0
24	but	but	O	CC	O	27	VMOD	0
25	surgical	surgical	B-NP	JJ	O	26	NMOD	0
26	reconstruction	reconstruction	I-NP	NN	O	27	SUB	0
27	may	may	B-VP	MD	O	39	VMOD	0
28	be	be	I-VP	VB	O	27	VC	0
29	the	the	B-NP	DT	O	31	NMOD	0
30	only	only	I-NP	JJ	O	31	NMOD	0
31	option	option	I-NP	NN	O	28	PRD	0
32	in	in	B-PP	IN	O	31	NMOD	0
33	advanced	advance	B-NP	VBN	O	34	NMOD	0
34	stages	stage	I-NP	NNS	O	32	PMOD	0
35	,	,	O	,	O	39	P	0
36	and	and	O	CC	O	39	VMOD	0
37	even	even	B-ADVP	RB	O	39	VMOD	0
38	this	this	B-NP	DT	O	39	SUB	0
39	is	be	B-VP	VBZ	O	0	ROOT	0
40	not	not	O	RB	O	39	VMOD	0
41	always	always	B-ADVP	RB	O	39	VMOD	0
42	an	an	B-NP	DT	O	43	NMOD	0
43	option	option	I-NP	NN	O	39	PRD	0
44	.	.	O	.	O	39	P	0

1	An	An	B-NP	DT	O	6	NMOD	0
2	alternative	alternative	I-NP	JJ	O	5	AMOD	0
3	and	and	I-NP	CC	O	5	AMOD	0
4	rather	rather	I-NP	RB	O	5	AMOD	0
5	obvious	obvious	I-NP	JJ	O	6	NMOD	0
6	strategy	strategy	I-NP	NN	O	10	SUB	0
7	to	to	B-VP	TO	O	8	VMOD	0
8	treat	treat	I-VP	VB	O	6	NMOD	0
9	ischemia	ischemia	B-NP	NN	O	8	OBJ	0
10	is	be	B-VP	VBZ	O	0	ROOT	0
11	to	to	B-VP	TO	O	12	VMOD	0
12	activate	activate	I-VP	VB	O	10	PRD	17	activate
13	endogenous	endogenous	B-NP	JJ	O	16	AMOD	0
14	angiogenic	angiogenic	I-NP	JJ	O	16	AMOD	3	angiogenic
15	or	or	I-NP	CC	O	16	AMOD	0
16	arteriogenic	arteriogenic	I-NP	JJ	O	17	NMOD	0
17	pathways	pathway	I-NP	NNS	O	12	OBJ	0
18	to	to	B-VP	TO	O	19	VMOD	0
19	stimulate	stimulate	I-VP	VB	O	12	VMOD	17	stimulate
20	revascularization	revascularization	B-NP	NN	O	19	OBJ	3	revascularization
21	of	of	B-PP	IN	O	20	NMOD	0
22	the	the	B-NP	DT	O	23	NMOD	0
23	tissue	tissue	I-NP	NN	O	21	PMOD	0
24	.	.	O	.	O	10	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	feasibility	feasibility	I-NP	NN	O	7	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	such	such	B-NP	JJ	O	6	NMOD	0
5	a	a	I-NP	DT	O	6	NMOD	0
6	strategy	strategy	I-NP	NN	O	3	PMOD	0
7	has	have	B-VP	VBZ	O	28	VMOD	0
8	now	now	I-VP	RB	O	7	VMOD	0
9	been	be	I-VP	VBN	O	7	VC	0
10	established	establish	I-VP	VBN	O	9	VC	0
11	through	through	B-PP	IN	O	10	VMOD	0
12	the	the	B-NP	DT	O	13	NMOD	0
13	results	result	I-NP	NNS	O	11	PMOD	0
14	of	of	B-PP	IN	O	13	NMOD	0
15	studies	study	B-NP	NNS	O	14	PMOD	0
16	over	over	B-PP	IN	O	15	NMOD	0
17	the	the	B-NP	DT	O	19	NMOD	0
18	past	past	I-NP	JJ	O	19	NMOD	0
19	decade	decade	I-NP	NN	O	16	PMOD	0
20	,	,	O	,	O	28	P	0
21	and	and	O	CC	O	24	NMOD	0
22	a	a	B-NP	DT	O	24	NMOD	0
23	new	new	I-NP	JJ	O	24	NMOD	0
24	discipline	discipline	I-NP	NN	O	28	SUB	0
25	called	call	B-VP	VBN	O	24	NMOD	0
26	therapeutic	therapeutic	B-NP	JJ	O	27	NMOD	0
27	angiogenesis	angiogenesis	I-NP	NN	O	25	VMOD	3	angiogenesis
28	has	have	B-VP	VBZ	O	0	ROOT	0
29	emerged	emerge	I-VP	VBN	O	28	VC	0
30	.	.	O	.	O	28	P	0

1	This	This	B-NP	DT	O	2	NMOD	0
2	review	review	I-NP	NN	O	3	SUB	0
3	focuses	focus	B-VP	VBZ	O	0	ROOT	0
4	on	on	B-PP	IN	O	3	VMOD	0
5	the	the	B-NP	DT	O	6	NMOD	0
6	application	application	I-NP	NN	O	4	PMOD	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	therapeutic	therapeutic	B-NP	JJ	O	9	NMOD	0
9	angiogenesis	angiogenesis	I-NP	NN	O	7	PMOD	3	angiogenesis
10	for	for	B-PP	IN	O	6	NMOD	0
11	treating	treat	B-VP	VBG	O	10	PMOD	0
12	ischemic	ischemic	B-NP	JJ	O	14	NMOD	0
13	muscle	muscle	I-NP	NN	O	14	NMOD	0
14	disease	disease	I-NP	NN	O	11	OBJ	0
15	and	and	O	CC	O	3	VMOD	0
16	includes	include	B-VP	VBZ	O	3	VMOD	0
17	a	a	B-NP	DT	O	19	NMOD	0
18	critical	critical	I-NP	JJ	O	19	NMOD	0
19	evaluation	evaluation	I-NP	NN	O	24	NMOD	0
20	of	of	B-PP	IN	O	19	NMOD	0
21	the	the	B-NP	DT	O	22	NMOD	0
22	parameters	parameter	I-NP	NNS	O	20	PMOD	0
23	and	and	I-NP	CC	O	24	NMOD	0
24	limitations	limitation	I-NP	NNS	O	16	OBJ	0
25	of	of	B-PP	IN	O	24	NMOD	0
26	current	current	B-NP	JJ	O	27	NMOD	0
27	procedures	procedure	I-NP	NNS	O	25	PMOD	0
28	.	.	O	.	O	3	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	development	development	I-NP	NN	O	6	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	this	this	B-NP	DT	O	5	NMOD	0
5	technology	technology	I-NP	NN	O	3	PMOD	0
6	has	have	B-VP	VBZ	O	0	ROOT	0
7	benefited	benefit	I-VP	VBN	O	6	VC	0
8	from	from	B-PP	IN	O	7	VMOD	0
9	its	its	B-NP	PRP$	O	10	NMOD	0
10	application	application	I-NP	NN	O	8	PMOD	0
11	to	to	B-PP	TO	O	8	PMOD	0
12	both	both	O	CC	O	11	PMOD	0
13	peripheral	peripheral	B-NP	JJ	O	17	NMOD	0
14	and	and	I-NP	CC	O	17	NMOD	0
15	coronary	coronary	I-NP	JJ	O	17	NMOD	0
16	artery	artery	I-NP	NN	O	17	NMOD	0
17	disease	disease	I-NP	NN	O	12	PMOD	0
18	and	and	O	CC	O	6	VMOD	0
19	results	result	B-VP	VBZ	O	6	VMOD	0
20	from	from	B-PP	IN	O	19	VMOD	0
21	both	both	B-NP	DT	O	22	SUB	0
22	are	be	B-VP	VBP	O	20	SBAR	0
23	reviewed	review	I-VP	VBN	O	22	VC	0
24	here	here	B-ADVP	RB	O	23	VMOD	0
25	.	.	O	.	O	6	P	0

